August 27, 2026 | Intelligent Congress, Pharma, healthcare
This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.

Congresses remain one of the most influential moments in the HCP journey, but many organizations still struggle to connect strategy, engagement, and measurement across the congress lifecycle. As a result, valuable opportunities to maximize impact are often missed.
Our latest Intelligent Congress guidebook introduces a practical four-step framework to help pharma teams transform congresses from isolated activities into connected, measurable experiences. Covering strategic alignment, integrated measurement, seamless HCP engagement, and streamlined execution, it provides a roadmap for creating more coordinated congress strategies that deliver greater business impact.
Download here.
This content was provided by Inizio
Latest Content from Inizio
Pegasus has expanded its pharma & life sciences senior team by appointing a new Associate Director and promoting two members of the existing team to Account Directors.
Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single…
As predicted, the vaccine market in emerging and developing countries has continued to expand. While the global vaccine market is expected to grow at around 12% annually over the next…
Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST
The patient journey is changing. Patients are now much more educated and engaged. They have access to information and want to be involved in decisions around their treatment programme. Technology…
The challenge:Our client needed to understand moleculardiagnostic testing growth opportunities for a new biomarker in oncology. They wanted to understand the current market landscape, identify potential leverage points that would maximise use of the biomarker…
Research Partnership has published new Living with rheumatoid arthritis (RA) EU and US market reports for 2016.
Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director
Immuno-oncology therapies which harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. However, these therapies come with a very high price…
Published in Quirk’s Marketing Research Review, April 2016, By Marc Yates, Director of Emerging Markets
